Replication rates of mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Raffetseder, Johanna ^a   Pienaar, Elsje ^a,b,c   Blomgran, Robert ^a   Eklund, Daniel ^a   Brodin, Veronika Patcha ^a   Andersson, Henrik ^a   Welin, Amanda ^a,d   Lerm, Maria ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ADAPTIVE IMMUNITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; IMMUNE SYSTEM; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; TUBERCULOSIS; ANTIBIOTIC RESISTANCE; BACTERIAL LOAD; CELL PROLIFERATION; DNA REPLICATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PATHOGENICITY; TIME FACTOR;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL LOAD; CELL PROLIFERATION; DNA REPLICATION; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; TIME FACTORS; TUBERCULOSIS;

EID: 84919341505     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112426     Document Type: Article

References (42)

1. Lawn SD, Zumla AI (2011) Tuberculosis. Lancet 378: 57-72.
2. Schon T, Lerm M, Stendahl O (2013) Shortening the 'short-course' therapyinsights into host immunity may contribute to new treatment strategies for tuberculosis. J Intern Med 273: 368-382.
3. Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64: 2062-2069.
4. Youatt J (1960) The uptake of isoniazid and related compounds by Mycobacteria. Aust J Exp Biol Med Sci 38: 331-337.
5. Zabinski RF, Blanchard JS (1997) The Requirement for Manganese and Oxygen in the Isoniazid-Dependent Inactivation of Mycobacterium tuberculosis Enoyl Reductase. J Am Chem Soc 119: 2331-2332.
6. Magliozzo RS, Marcinkeviciene JA (1996) Evidence for Isoniazid Oxidation by Oxyferrous Mycobacterial Catalase2Peroxidase. J Am Chem Soc 118.
7. Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, et al. (2000) Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356: 2133-2138.
8. Young DB, Gideon HP, Wilkinson RJ (2009) Eliminating latent tuberculosis. Trends Microbiol 17: 183-188.
9. McCune RM Jr, McDermott W, Tompsett R (1956) The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104: 763-802.
10. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, et al. (2008) Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76: 2333-2340.
11. Aly S, Wagner K, Keller C, Malm S, Malzan A, et al. (2006) Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 210: 298-305.
12. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, et al. (2006) Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 8: 218-232.
13. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, et al. (2009) A replication clock for Mycobacterium tuberculosis. Nat Med 15: 211-214.
14. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE (2011) Mycobacterium tuberculosis Uses Host Triacylglycerol to Accumulate Lipid Droplets and Acquires a Dormancy-Like Phenotype in Lipid-Loaded Macrophages. PLoS Pathog 7: e1002093.
15. Estrella JL, Kan-Sutton C, Gong X, Rajagopalan M, Lewis DE, et al. (2011) A Novel in vitro Human Macrophage Model to Study the Persistence of Mycobacterium tuberculosis Using Vitamin D(3) and Retinoic Acid Activated THP-1 Macrophages. Front Microbiol 2: 67.
16. Vogt G, Nathan C (2011) In vitro differentiation of human macrophages with enhanced antimycobacterial activity. J Clin Invest 121: 3889-3901.
17. Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, et al. (2009) A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 4: e6077.
18. Welin A, Raffetseder J, Eklund D, Stendahl O, Lerm M (2011) Importance of phagosomal functionality for growth restriction of Mycobacterium tuberculosis in primary human macrophages J Innate Immun 3: 508-518.
19. Rohde KH, Veiga DF, Caldwell S, Balazsi G, Russell DG (2012) Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog 8: e1002769.
20. Muñoz-Elías E, Timm J, Botha T, Chan W-T, Gomez J, et al. (2005) Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 73: 546-551.
21. Lin P, Ford C, Coleman M, Myers A, Gawande R, et al. (2014) Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nature Med 20: 75-79.
22. Sherman DR, Sabo PJ, Hickey MJ, Arain TM, Mahairas GG, et al. (1995) Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci U S A 92: 6625-6629.
23. Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, et al. (2013) Dynamic persistence of antibiotic-stressed mycobacteria. Science 339: 91-95.
24. Santi I, Dhar N, Bousbaine D, Wakamoto Y, McKinney JD (2013) Single-cell dynamics of the chromosome replication and cell division cycles in mycobacteria. Nat Commun 4: 2470.
25. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
26. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown IN, et al. (1999) Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67: 4586-4593.
27. Seiler P, Ulrichs T, Bandermann S, Pradl L, Jorg S, et al. (2003) Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis 188: 1326-1331.
28. Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, et al. (2008) Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5: e75.
29. Zhang Y, Scorpio A, Nikaido H, Sun Z (1999) Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181: 2044-2049.
30. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, et al. (2011) Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145: 39-53.
31. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, et al. (2008) Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4: e1000204.
32. Caceres N, Tapia G, Ojanguren I, Altare F, Gil O, et al. (2009) Evolution of foamy macrophages in the pulmonary granulomas of experimental tuberculosis models. Tuberculosis (Edinb) 89: 175-182.
33. Welin A, Eklund D, Stendahl O, Lerm M (2011) Human Macrophages Infected with a High Burden of ESAT-6-Expressing M. tuberculosis Undergo Caspase-1-and Cathepsin B-Independent Necrosis. PLoS One 6: e20302.
34. Bhatt A, Fujiwara N, Bhatt K, Gurcha SS, Kremer L, et al. (2007) Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc Natl Acad Sci U S A 104: 5157-5162.
35. Tailleux L, Waddell SJ, Pelizzola M, Mortellaro A, Withers M, et al. (2008) Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One 3: e1403.
36. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622-1625.
37. Helaine S, Cheverton A, Watson K, Faure L, Matthews S, et al. (2014) Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science 343: 204-208.
38. Zumla A, Atun R, Maeurer M, Mwaba P, Ma Z, et al. (2011) Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health TM & IH 16: 79-83.
39. Dhillon J, Mitchison DA (1989) Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254. Antimicrob Agents Chemother 33: 1255-1259.
40. Rastogi N, Labrousse V, Goh KS (1996) In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33: 167-175.
41. Eklund D, Welin A, Schon T, Stendahl O, Huygen K, et al. (2010) Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis. Clin Vaccine Immunol 17: 513-517.
42. Garton NJ, Christensen H, Minnikin DE, Adegbola RA, Barer MR (2002) Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 148: 2951-2958.